journal
MENU ▼
Read by QxMD icon Read
search

Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine

journal
https://www.readbyqxmd.com/read/29777009/feasibility-of-cxcr4-directed-radioligand-therapy-in-advanced-diffuse-large-b-cell-lymphoma
#1
Constantin Lapa, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, Gerd Wunderlich, Rudolf Werner, Samuel Samnick, Jörg Kotzerke, Hermann Einsele, Andreas Buck, Hans-Jürgen Wester, Götz Ulrich Grigoleit
We have recently reported on our experience with C-X-C-motif chemokine receptor 4- (CXCR4-) directed radioligand therapy (RLT) in multiple myeloma and acute leukemia. Methods: Six patients with heavily pre-treated relapsed diffuse large B cell lymphoma (DLBCL) (3 males, 3 females; aged, 54±8 years) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation (SCT). In 2 patients, radioimmunotherapy (RIT) targeting CD20 or CD66 was added to enhance anti-lymphoma activity...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29777008/multispectral-fluorescence-imaging-as-a-tool-to-separate-healthy-and-disease-related-lymphatic-anatomies-during-robot-assisted-laparoscopic-procedures
#2
Philippa Meershoek, Gijs H KleinJan, Matthias N van Oosterom, Esther M Wit, Danny M van Willigen, Kevin P Bauwens, Erik J van Gennep, Alexandre M Mottrie, Henk G van der Poel, Fijs van Leeuwen
To reduce the invasive nature of extended pelvic lymph node dissections (ePLND) in prostate cancer, we have developed a multicolor fluorescence guidance approach that enables the discrimination between prostate draining lymph nodes (LNs) and lower limb draining LNs. Methods: In five porcine models multispectral-fluorescence guidance was performed using da Vinci Si- and Xi-robot consoles. They received fluorescein into the lower limb(s) and indocyanine green (ICG)-nanocolloid into the prostate. Results: Fluorescein was detected in 29 LNs (average of 3...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29777007/development-of-64-cu-nota-trastuzumab-for-her2-targeting-radiopharmaceutical-with-improved-pharmacokinetics-for-human-study
#3
Sang-Keun Woo, Su Jin Jang, Min-Jung Seo, Ju Hui Park, Byoung Soo Kim, Eun Jung Kim, Yong Jin Lee, Tae Sup Lee, Gwang Il An, In Ho Song, Youngho Seo, Kwang Il Kim, Joo Hyun Kang
Purpose The purpose of this study was to develop 64 Cu-labeled trastuzumab with improved pharmacokinetics for human epidermal growth factor receptor 2. Methods Trastuzumab was conjugated with SCN-Bn-NOTA and radiolabeled with 64 Cu. Serum stability and immunoreactivity of 64 Cu-NOTA-trastuzumab were tested. Small animal PET imaging and biodistribution study were performed in HER2-positive breast cancer xenograft model (BT-474). Internal dosimetry of experimental animals was performed using the image-based approach with the Monte Carlo N-Particle Code...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29777006/in-vivo-characterization-and-quantification-of-neurofibrillary-tau-pet-radioligand-18-f-mk-6240-in-humans-from-alzheimer-s-disease-dementia-to-young-controls
#4
Tobey J Betthauser, Karly A Cody, Matthew D Zammit, Dhanabalan Murali, Alexander K Converse, Todd E Barnhart, Charles K Stone, Howard A Rowley, Sterling C Johnson, Bradley T Christian
Tau positron emission tomography (PET) imaging has potential for elucidating changes in the deposition of neuropathological tau aggregates that are occurring during the progression of Alzheimer's disease (AD). This work investigates in vivo kinetics, quantification strategies and imaging characteristics of a novel tau PET radioligand [18 F]MK-6240 in humans. Methods: Fifty-one individuals ranging from cognitively normal young controls to persons with dementia underwent T1-weighted magnetic resonance imaging (MRI), and [11 C]PiB and [18 F]MK-6240 PET imaging...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29777005/predictors-of-survival-in-211-patients-with-stage-iv-pulmonary-and-gastroenteropancreatic-mibg-positive-neuroendocrine-tumors-treated-with-i-131-mibg
#5
Ari Kane, Matthew P Thorpe, Jorge D Oldan, Brandon A Howard, Jason Zhu, Michael A Morse, Terence Wong, Neil A Petry, Robert Reiman, Salvador Borges-Neto
Purpose: This retrospective analysis identifies predictors of survival in a cohort of patients with mIBG positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with I-131 mIBG therapy, in order to inform treatment selection and post-treatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from n = 211 P/GEP-NET patients treated with mIBG between 1991-2014. For patients with computed tomography (CT) follow up ( n = 125), imaging response was assessed by Response Evaluation Criteria on Solid Tumors (RECIST) 1...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29777004/development-of-a-novel-spect-tracer-to-image-c-met-expression-in-non-small-cell-lung-cancer-in-a-human-tumor-xenograft
#6
Zhaoguo Han, Yadi Xiao, Kai Wang, Ji Yan, Zunyu Xiao, Fang Fang, Zhongnan Jin, Yang Liu, Xilin Sun, Baozhong Shen
Rationale: Elevated expression of the c-Met receptor plays a crucial role in cancers. In non-small cell lung cancer (NSCLC), aberrant activation of c-Met signaling pathway contributes to tumorigenesis and cancer progression, and may mediate acquired resistance to epidermal growth factor receptor-targeted therapy. c-Met is therefore emerging as a promising therapeutic target for treating NSCLC, and the methods for noninvasive in vivo assessment of c-Met expression will improve NSCLC treatment and diagnosis. Methods: A new peptide-based (cMBP) radiotracer targeting c-Met, 99m Tc-hydrazine nicotinamide (HYNIC)-cMBP, was developed for single photon emission computed tomography (SPECT) imaging...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29777003/impact-of-reference-target-region-selection-on-amyloid-pet-standard-uptake-value-ratios-in-the-phase-1b-prime-study-of-aducanumab
#7
Ping Chiao, Barry J Bedell, Brian Avants, Alex P Zijdenbos, Marilyn Grand'Maison, Paul O'Neill, John O'Gorman, Tianle Chen, Robert Koeppe
Standardized uptake value ratios (SUVRs) are commonly used to quantify tracer uptake in amyloid beta positron emission tomography (Aβ-PET). Here, we explore the impact of target and reference region of interest (ROI) selection on SUVR effect size using interventional data from the ongoing Phase Ib PRIME study (NCT01677572) of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's disease (AD). Methods: Florbetapir PET SUVR was calculated at baseline (screening) and Weeks 26 and 54 for patients randomized to placebo and each of four aducanumab doses (1, 3, 6, and 10 mg/kg), using whole cerebellum, cerebellar grey matter, cerebellar white matter, pons, and subcortical white matter as reference regions...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29748237/an-overview-on-pet-radiochemistry-part-2-radiometals
#8
Marie Brandt, Jens Cardinale, Margaret Aulsebrook, Gilles Gasser, Thomas Mindt
This continuing educational review provides an overview on radiometals used for PET. General aspects of radiometal-based radiotracers are covered and the most frequently applied metallic PET radionuclides 68 Ga, 89 Zr, and 64 Cu are highlighted with a discussion of their strengths and limitations.
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29748236/modeling-and-predicting-tumor-response-in-radioligand-therapy
#9
Peter Kletting, Anne Thieme, Nina Eberhardt, Andreas Rinscheid, Calogero D'Alessandria, Jakob Allmann, Hans-Jürgen Wester, Robert Tauber, Ambros J Beer, Gerhard Glatting, Matthias Eiber
The aim of this work was to develop a theranostic method that allows predicting PSMA-positive tumor volume after radioligand therapy (RLT) based on a pre-therapeutic PET/CT measurement and physiologically based pharmacokinetic/dynamic (PBPK/PD) modeling at the example of RLT using 177 Lu-labeled PSMA for imaging and therapy (PSMA I&T). Methods: A recently developed PBPK model for 177 Lu PSMA I&T RLT was extended to account for tumor (exponential) growth and reduction due to irradiation (linear quadratic model)...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29748235/p-glycoprotein-abcb1-inhibits-the-influx-and-increases-the-efflux-of-11-c-metoclopramide-across-the-blood-brain-barrier-a-pet-study-on-non-human-primates
#10
Sylvain Auvity, Fabien Caillé, Solène Marie, Catriona Wimberley, Martin Bauer, Oliver Langer, Irène Buvat, Sébastien Goutal, Nicolas Tournier
Rationale : PET imaging using radiolabeled high-affinity substrates of P-glycoprotein (ABCB1) has convincingly revealed the role of this major efflux transporter in limiting the influx of its substrates from blood into the brain across the blood-brain barrier (BBB). Many drugs, such as metoclopramide, are weak ABCB1 substrates and distribute into the brain even when ABCB1 is fully functional. In this study, we used kinetic modeling and validated simplified methods to highlight and quantify the impact of ABCB1 on the BBB influx and efflux of 11 C-metoclopramide, as a model weak ABCB1 substrate, in non-human primates...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29748234/radioiodine-therapy-in-differentiated-thyroid-cancer-a-matter-of-controversy-pro-radioiodine
#11
Matthias Schmidt, Rainer Görges, Alexander Drzezga, Markus Dietlein
Radioiodine therapy is a matter of controversy as different opinions exist towards its use in patients with differentiated thyroid carcinoma. The following article sheds light on different opinions and explains why the authors advocate the use of radioiodine therapy not only in high-risk patients. In comparison to other malignancies differentiated thyroid carcinoma has a different tumor biology due to its usually slow growth pattern. Radioiodine therapy was first used about 75 years ago and provided cure at a time when prospective randomized controlled trials were to be developed...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29748233/prospective-study-of-serial-18-f-fdg-pet-and-18-f-fluoride-18-f-naf-pet-to-predict-time-to-skeletal-related-events-time-to-progression-and-survival-in-patients-with-bone-dominant-metastatic-breast-cancer
#12
Lanell M Peterson, Janet O'Sullivan, Qian Vicky Wu, Alena Novakova-Jiresova, Isaac Jenkins, Jean H Lee, Andrew Shields, Susan Montgomery, Hannah M Linden, Julie R Gralow, Vijayakrishna K Gadi, Mark Muzi, Paul E Kinahan, David A Mankoff, Jennifer M Specht
Assessing therapy response of breast cancer bone metastases is challenging. In retrospective studies, serial 18 F-FDG PET was predictive of time to skeletal related events (tSRE) and time-to-progression (TTP). 18 F-NaF PET improves bone metastasis detection compared to bone scans. We prospectively tested 18 F-FDG PET and 18 F-NaF PET to predict tSRE, TTP, and overall survival (OS) in patients with bone-dominant metastatic breast cancer (BD MBC). Methods: Patients with BD MBC were imaged with 18 F-FDG PET and 18 F-NaF PET prior to starting new therapy (scan1) and again at a range of times centered around approximately 4 months later (scan2)...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29728519/first-in-human-pet-study-of-3-novel-tau-radiopharmaceuticals-11-c-ro6924963-11-c-ro6931643-and-18-f-ro6958948
#13
Dean F Wong, Robert Comley, Hiroto Kuwabara, Paul B Rosenberg, Susan M Resnick, Susanne Ostrowitzki, Cristina Vozzi, Frank Boess, Esther Oh, Constantine G Lyketsos, Michael Honer, Luca Gobbi, Gregory Klein, Noble George, Lorena Gapasin, Kelly Kitzmiller, Joshua Roberts, Jeff Sevigny, Ayon Nandi, James R Brasic, Chakradhar Mishra, Madhav Thambisetty, Abhay Moghekar, Anil Mathur, Marilyn Albert, Robert F Dannals, Edilio Borroni
Background: [11 C]RO-963, [11 C]RO-643 and [18 F]RO-948 (previously referred as [11 C]RO6924963, [11 C]RO6931643, and [18 F]RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data (1,2). Here we describe the first human evaluation of these novel radiotracers. Methods: Amyloid PET positive Alzheimer's disease (AD) patients and young healthy subjects (YC) each received two different tau tracers. Dynamic 90 min scans were obtained after bolus injection of [11 C]RO-963, [11 C]RO-643 or [18 F]RO-948...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29728518/dual-isotope-cryo-imaging-quantitative-autoradiography-ciqa-anvestigating-antibody-drug-conjugate-distribution-and-payload-delivery-through-imaging
#14
Ohad Ilovich, Mohammed Qutaish, Jacob Hesterman, Kelly Orcutt, Jack Hoppin, Ildiko Polyak, Marc Seaman, Adnan Abu-Yousif, Donna Cvet, Daniel Bradley
In vitro properties of antibody drug conjugates (ADCs) such as binding, internalization, and cytotoxicity are often well characterized prior to in vivo studies. Interpretation of in vivo studies could significantly be enhanced by molecular imaging tools. We present here a dual-isotope cryo-imaging quantitative autoradiography (CIQA) methodology combined with advanced 3D imaging and analysis allowing for the simultaneous study of both antibody and payload distribution in tissues of interest. in a pre-clinical setting...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29728517/a-first-in-man-study-of-68-ga-nanocolloid-pet-ct-sentinel-lymph-node-imaging-in-prostate-cancer-demonstrates-aberrant-lymphatic-drainage-pathways
#15
Jacki A Doughton, Michael S Hofman, Peter Eu, Rodney J Hicks, Scott G Williams
Purpose: To assess feasibility, safety and utility of a novel 68 Ga-nanocolloid radio-tracer with PET-CT lymphoscintigraphy for identification of sentinel lymph nodes (SLN). Methods: Pilot study of patients from a tertiary cancer hospital who required insertion of gold fiducials for prostate cancer radiation therapy. Participation did not affect cancer management. Ultrasound-guided transperineal intra-prostatic injection of PET tracer (iron oxide nanocolloid labelled with gallium-68) after placement of fiducials...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29728516/the-effect-of-including-bone-in-dixon-based-attenuation-correction-for-18-f-fluciclovine-pet-mri-of-prostate-cancer
#16
Mattijs Elschot, Kirsten M Selnæs, Håkon Johansen, Brage Krüger-Stokke, Helena Bertilsson, Tone F Bathen
The objective of this study was to evaluate the effect of including bone in DIXON-based attenuation correction for 18 F-fluciclovine Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI) of primary and recurrent prostate cancer. Methods: 18 F-fluciclovine PET data from two PET/MRI studies - one for staging of high-risk prostate cancer (28 patients) and one for diagnosis of recurrent prostate cancer (81 patients) - were reconstructed with a 4-compartment (reference) and 5-compartment attenuation map...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29728515/interobserver-agreement-of-interim-and-end-of-treatment-18-f-fdg-pet-ct-in-diffuse-large-b-cell-lymphoma-dlbcl-impact-on-clinical-practice-and-trials
#17
Coreline N Burggraaff, Alexander C Cornelisse, Otto S Hoekstra, Pieternella J Lugtenburg, Bart de Keizer, Anne I J Arens, Filiz Celik, Julia E Huijbregts, Henrica C W De Vet, Josee M Zijlstra
We aimed to assess the interobserver agreement of Interim PET (I-PET) and End-of-Treatment PET (EoT-PET) using the Deauville 5-point scale (DS) in first-line DLBCL patients. Methods: I-PET and EoT-PET scans of DLBCL patients were performed in the HOVON84 study (2007-2012), an international multicenter randomized controlled trial. Patients received R-CHOP14 and were randomized to receive rituximab intensification in the first 4 cycles or not. I-PET was made after 4 cycles (for observational purposes), and EoT-PET scan after 6 or 8 cycles...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29728514/positron-emission-tomography-of-adoptively-transferred-chimeric-antigen-receptor-t-cells-with-zirconium-89-oxine
#18
Michael Ryan Weist, Renate Starr, Brenda Aguilar, Junie Chea, Joshua Miles, Erasmus Poku, Ethan Gerdts, Xin Yang, Saul Priceman, Stephen Forman, David Colcher, Christine Brown, John Shively
CAR T cell therapy is a promising clinical approach for reducing tumor progression and prolonging patient survival. However, improvements in both the safety and potency of CAR T cell therapy demand quantitative imaging techniques to determine the distribution of cells following adoptive transfer. The purpose of this study is to optimize zirconium-89-oxine (89 Zr-oxine) labeling of chimeric antigen receptor (CAR) T cells and evaluate positron emission tomography (PET) as a platform for imaging adoptively transferred CAR T cells...
May 4, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29700130/embrace-progress
#19
Kevin Bradley, Daniel R McGowan, Fergus V Gleeson, Geoffrey B Johnson, Jason R Young, Craig S Levin, Guido A Davidzon, Andrei H Iagaru
No abstract text is available yet for this article.
April 26, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29700129/regional-myocardial-perfusion-disturbance-in-experimental-chronic-chagas-cardiomyopathy
#20
Luciano F L Oliveira, James T Thackeray, José A Marin Neto, Minna M D Romano, Eduardo E V Carvalho, Jorge Mejia, Denise M Tanaka, Grace K Silva, Douglas R Abdalla, Carlos Malamut, Frank M Bengel, Maria L Higuchi, André Schmidt, Edécio Cunha-Neto, Marcus V Simões
Background: Altered myocardial perfusion is a common finding in chronic Chagas cardiomyopathy (CCC), but its underlying histologic changes have not been elucidated. We investigated the occurrence of myocardial perfusion defects (MPD) and the correlated regional changes to histology in an experimental model of CCC in hamsters. Methods: Female Syrian hamsters ( n = 34) were infected with 3.5x104 to 105 trypomastigote forms of T. cruzi Y-strain and 6 to 10 months afterwards were submitted to in vivo imaging including: rest 99m Tc-sestamibi SPECT imaging, segmental and global left ventricular (LV) function assessment by using 2D-echocardiogram, and 18 F-FDG PET for evaluation of myocardial viability...
April 26, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
journal
journal
20164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"